Skip to main content

Decrease in Fungizone™ Toxicity Induced by the Use of Lipofundin™ As a Dilutent: An In Vitro Study

Buy Article:

$68.00 + tax (Refund Policy)

The aim of this work was to develop an in vitro experimental protocol for the evaluation of toxicity and efficacy of an amphotericin B (AmB) micelle system, Fungizone™, which was previously diluted with a lipid based emulsion for parenteral use, named Lipofundin™ LCT/MCT-20%. Two cell models were used for the experiments: Red Blood Cells (RBC) from human donnors and Candida tropicalis (Ct). These models were used to perform the toxicity and activity of the Fungizone™/ Lipofundin™ admixture (AmB-LP) and the Fungizone™ (AmB-M) alone. While potassium (K+) and hemoglobin leakage from RBC were the parameters used to evaluate the acute and chronic toxicity, respectively, the efficacy of AmB-LP and AmB-M were assessed by K+ leakage or cell survival rate (CSR) from Ct. The results show that the toxicity of AmB-LP to RBC was concentration dependent concerning the K+ leakage; while at high concentrations, 5 and 50 mg.mL-1, the leakage was 50.91 ± 2.09% and 95.71 ± 0.64%, respectively, at a concentration of 0.5 mg.mL-1 this value was 17.16 ± 1.57% and the value tended to zero for the lowest concentration studied, 0.05 mg.mL-1. Surprisingly, AmB-LP induced very low hemoglobin leakage for all concentrations studied. At the highest concentration, 50 mg.mL-1, this value was around 3%. When the cell model was Ct, the results changed completely. Not only high concentrations of AmB-LP, but also lower ones were able to induce a K+ permeability of around 100%. The CSR parameter showed an inverse correlation with the concentration; high values, between 50 and 5 mg.mL-1, resulted in a CSR of around 8%. On the other hand, for lower concentration values, 0.05 and 0.5 mg.mL-1, this one was around 80%. The same profile of activity against Ct was found for AmB-M. Only a small variation was found for the K+ leakage at 0.05 mg.mL-1 that presented a value of 96.99 ± 2.53%. However, AmB-M seemed to be much more toxic than AmB-LP. Its induction of hemoglobin leakage started at 0.5 mg.mL-1 and reached the 100% at 5 mg.mL-1. K+ leakage results were worse. The intermediate concentrations of study, 0.5 and 5 mg.mL-1, presented a significant increase compared to AmBLP. All together these results reveal that the activity of AmB is not only concentration dependent, but also depends on the drug carrier in which this compound was inserted. The AmB-LP preparation showed the same efficacy as AmB-M, but with a low toxicity. Therefore, AmB-LP presented a higher therapeutic index that permits the administration of high concentration of AmB without revealing side effects. However, the simple mixture of two complex pharmaceutical entities, as micelles and emulsions, should be analyzed carefully to assure that physicochemical stability is not reduced and thereby cause a different biodistribution in vivo.

Keywords: amphotericin b; drug delivery; emulsion; fungal infection; fungizoneo; lipofundino; red blood cells

Document Type: Review Article

Affiliations: Departamento de Farmacia, Rua Praia de Areia Branca, 8948, Natal-RN, 59094-450, Brazil.

Publication date: 01 April 2005

More about this publication?
  • The aim of Current Drug Delivery is to publish peer-reviewed articles, short communications, short and in-depth reviews in the rapidly developing field of drug delivery. Modern drug research aims to build in delivery properties of a drug at the design phase, however in many cases this ideal cannot be met and the development of delivery systems becomes as important as the development as the drugs themselves.

    The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance.

    The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content